26 results on '"Takaomi Sagawa"'
Search Results
2. Long‐term outcome of Wilson's disease complicated by liver disease
- Author
-
Satoko Arai, Tomomi Kogiso, Yuri Ogasawara, Takaomi Sagawa, Makiko Taniai, and Katsutoshi Tokushige
- Subjects
acute liver failure ,aspartate aminotransferase to platelet ratio index ,fibrosis‐4 index ,liver transplantation ,Wilson's disease ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Abstract Background and Aim Wilson's disease (WD) is a rare inherited disease that causes systemic copper accumulation. This study examined the long‐term course of WD patients with liver disease. Methods The 12 patients (9 female patients) enrolled in the study had a median age of 28 years (range: 19–57 years) at their first visit to our hospital. Clinical course and fibrosis markers were assessed in all patients. Results The median age at diagnosis was 24 years (range: 5–42 years). One patient had acute liver failure (ALF) and 11 patients had chronic liver disease (CLD, 5 with cirrhosis). The patients were followed‐up for >20 years. The patient with ALF underwent liver transplantation; the postoperative course during the subsequent 20 years was good. Of the six patients with CLD, liver cirrhosis developed in four patients with interrupted chelating therapy. Two of the patients with cirrhosis died; one of these two patients died at 21 years after liver transplantation. However, the remaining patients with continued treatment exhibited a favorable clinical course for 30 years and none developed hepatocellular carcinoma (HCC). The duration of chelation therapy was significantly negatively correlated (P
- Published
- 2021
- Full Text
- View/download PDF
3. Prevalence of fatty liver disease after liver transplantation and risk factors for recipients and donors
- Author
-
Kentaro Horiuchi, Tomomi Kogiso, Takaomi Sagawa, Makiko Taniai, Yoshito Kotera, Hiroto Egawa, and Katsutoshi Tokushige
- Subjects
Fatty liver disease (FLD) ,Liver transplantation (LT) ,Everolimus (EVL) ,Specialties of internal medicine ,RC581-951 - Abstract
Introduction and objectives: Fatty liver disease (FLD) may develop in liver transplant recipients. We investigated the recipient and donor risk factors for FLD development after liver transplantation (LT). Methods: A total of 108 liver transplant recipients (54 men [50.0%]; median age, 52 [20–68] years) treated from 2011–2020 was enrolled. Three recipients died at
- Published
- 2022
- Full Text
- View/download PDF
4. Risk factors for Fontan-associated hepatocellular carcinoma.
- Author
-
Tomomi Kogiso, Takaomi Sagawa, Makiko Taniai, Eriko Shimada, Kei Inai, Tokuko Shinohara, and Katsutoshi Tokushige
- Subjects
Medicine ,Science - Abstract
AimsThe incidence of hepatocellular carcinoma (HCC) in patients with Fontan-associated liver disease (i.e., FALD-HCC) has increased over time. However, the risk factors for HCC development remain unclear. Here, we compared the levels of non-invasive markers to the survival rate of FALD-HCC patients.MethodsFrom 2003 to 2021, 154 patients (66 men, 42.9%) developed liver disease after undergoing Fontan procedures. HCC was diagnosed in 15 (9.7%) (8 men, 53.3%) at a median age of 34 years (range, 21-45 years). We compared FALD-HCC and non-HCC cases; we generated marker level cutoffs using receiver operating characteristic curves. We sought to identify risk factors for HCC and mortality.ResultsThe incidence of HCC was 4.9% in FALD patients within 20 years after the Fontan procedure. Compared with non-HCC patients, FALD-HCC patients exhibited higher incidences of polysplenia and esophageal varices. At the time of HCC development, the hyaluronic acid (HA) level (p = 0.04) and the fibrosis-4 index (p = 0.02) were significantly higher in FALD-HCC patients than in non-HCC patients; the total bilirubin (T-BIL) level (p = 0.07) and the model for end-stage liver disease score [excluding the international normalized ratio (MELD-XI)] (p = 0.06) tended to be higher in FALD-HCC patients. Within approximately 20 years of the Fontan procedure, 10 patients died (survival rate, 96.9%). Kaplan-Meier curve analysis indicated that patients with T-BIL levels ≥ 2.2 mg/dL, HA levels ≥ 55.5 ng/mL, and MELD-XI scores ≥ 18.7 were at high risk of HCC, a generally poor prognosis, and both polysplenia and esophageal varices. Multivariate Cox regression analyses indicated that the complication of polysplenia [Hazard ratio (HR): 10.915] and a higher MELD-XI score (HR: 1.148, both p < 0.01) were independent risk factors for FALD-HCC.ConclusionsThe complication of polysplenia and a MELD-XI score may predict HCC development and mortality in FALD patients.
- Published
- 2022
- Full Text
- View/download PDF
5. Impact of continued administration of tolvaptan on cirrhotic patients with ascites
- Author
-
Tomomi Kogiso, Takaomi Sagawa, Kazuhisa Kodama, Makiko Taniai, and Katsutoshi Tokushige
- Subjects
Vasopressin V2-receptor antagonist ,Tolvaptan ,Liver cirrhosis ,Body weight reduction ,Long-term outcome ,Therapeutics. Pharmacology ,RM1-950 ,Toxicology. Poisons ,RA1190-1270 - Abstract
Abstract Background The vasopressin V2-receptor antagonist tolvaptan is used to treat cirrhotic patients with ascites. We investigated the outcome of long-term treatment. Methods This was a single-center retrospective study. Overall, 170 cirrhotic patients (95 males, median age 63 years) were enrolled and received tolvaptan orally after hospitalization for ascites, which included treatment with conventional diuretics. We compared patients who withdrew tolvaptan treatment after
- Published
- 2018
- Full Text
- View/download PDF
6. Outcomes of Japanese patients with non-alcoholic fatty liver disease according to genetic background and lifestyle-related diseases
- Author
-
Tomomi Kogiso, Takaomi Sagawa, Kazuhisa Kodama, Makiko Taniai, Etsuko Hashimoto, and Katsutoshi Tokushige
- Subjects
Non-alcoholic fatty liver disease (NAFLD) ,Mortality ,Single nucleotide polymorphism (SNP) ,Patatin-like phospholipase 3 (PNPLA3) ,Aldehyde dehydrogenase 2 (ALDH2) ,Specialties of internal medicine ,RC581-951 - Abstract
Introduction and objectives: Genetic background may be involved in the mechanisms of liver injury and the development of non-alcoholic fatty liver disease (NAFLD). However, its contributions to the long-term outcome of NAFLD have been unclear. Methods: We enrolled 314 Japanese patients with biopsy-confirmed NAFLD from 2000 to 2018 (161 men [51.3%]; median age, 53 [14–84] years; 114 with advanced fibrosis [37.5%]) in the patients without hepatocellular carcinoma at diagnosis. Genomic DNA was extracted from peripheral blood and single nucleotide polymorphisms (SNPs) were analyzed. Associations of mortality with patatin-like phospholipase 3 (PNPLA3) and aldehyde dehydrogenase 2 (ALDH2) were analyzed. Finally, a subgroup analysis according to lifestyle-related disease was performed. Results: During the median 7 years of follow-up, 20 patients (6.4%) died (13 liver-related [4.1%] and 7 non-liver-related deaths [2.2%]). Patients with ALDH2 (non-GG genotype) who had reduced alcohol metabolism tended to have a poor prognosis (p = 0.06). Patients carrying both risk SNPs of PNPLA3 (GG) and ALDH2 (non-GG) had a significantly poor prognosis (p = 0.01). In the subgroup analysis, patients with PNPLA3 (GG) who were non-diabetics (p = 0.06) or non-dyslipidemic (p = 0.03), with ALDH2 (non-GG) who were non-dyslipidemic (p = 0.01) or hypertensive (p = 0.03), also had a poor prognosis. The Cox analysis revealed that ALDH2 (non-GG) was associated with a poor prognosis (Hazard ratio: 4.568, 95% Confidence Interval: 1.294–16.131, p = 0.02) similar to the liver function tests. Conclusions: Genetic background may affect NAFLD prognosis and ALDH2 SNP could predict the outcome.
- Published
- 2021
- Full Text
- View/download PDF
7. Characteristics of NAFLD Based on Hypopituitarism
- Author
-
Kazuhisa Kodama, Atsuhiro Ichihara, Yasufumi Seki, Yuichi Ikarashi, Takaomi Sagawa, Tomomi Kogiso, Maiko Taniai, and Katsutoshi Tokushige
- Subjects
Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Background. Hypopituitarism and hypothalamic disorders, which induce central obesity and appetite disorder, are associated with nonalcoholic fatty liver disease (NAFLD). We retrospectively analyzed the clinical features of NAFLD patients with hypopituitarism. Patients. We examined the cases of 15 NAFLD patients with hypopituitarism (mean age, 39.4 years; males/females, 11/4). The causes of hypopituitarism were surgical in eight cases (six with craniopharyngioma and two with prolactinoma) and nonsurgical in seven cases, including unexplained hypopituitarism in five cases, Sheehan syndrome in one case, and one case that occurred after the radiation therapy. Serum adiponectin, soluble tumor necrosis factor receptor-2 (TNFR-2), and leptin levels were measured. Results. We compared the cases of the eight patients who underwent cranial surgery due to craniopharyngioma or prolactinoma and seven nonsurgical cases. The body mass index (surgery group, 30.2 ± 4.1; nonsurgery group, 29.2 ± 14.2) and the rate of diabetes (75% in surgery group, 14.3% in nonsurgery group) tended to be higher in the surgery group, and the hepatic fibrosis grade (surgery group, 3.75 ± 0.38; nonsurgery group, 1.64 ± 1.07) was significantly higher in the surgery group. The levels of adipocytokines, serum adiponectin, and serum soluble TNFR-2 showed no correlation with hepatic fibrosis, whereas the serum leptin levels were significantly correlated with liver fibrosis (R = 0.696). Conclusion. The hepatic fibrosis grade rapidly progressed in the cranial surgery cases of NAFLD patients with hypopituitarism, possibly in association with BMI, diabetes mellitus, and leptin. In such cranial surgery patients, strong interventions should be considered from the early stage, including diet education, hormone replacement, and more.
- Published
- 2020
- Full Text
- View/download PDF
8. Risk and protective factors of acute kidney injury in decompensated cirrhotic patients with ascites on tolvaptan
- Author
-
Makiko Taniai, Takaomi Sagawa, Katsutoshi Tokushige, Yuri Ogasawara, and Tomomi Kogiso
- Subjects
proton pump inhibitor/H2 blockers ,medicine.medical_specialty ,Cirrhosis ,liver cirrhosis ,kanamycin/rifaximin ,Tolvaptan ,RC799-869 ,urologic and male genital diseases ,Gastroenterology ,chemistry.chemical_compound ,Internal medicine ,Ascites ,Medicine ,Hepatic encephalopathy ,Hepatology ,tolvaptan ,business.industry ,Acute kidney injury ,Original Articles ,Diseases of the digestive system. Gastroenterology ,medicine.disease ,female genital diseases and pregnancy complications ,Rifaximin ,acute kidney injury ,chemistry ,Original Article ,medicine.symptom ,business ,Complication ,Kidney disease ,medicine.drug - Abstract
Background and Aim Acute kidney injury (AKI) is a life‐threatening complication of liver cirrhosis. Here, we evaluated the risk factors and characteristics of AKI in cirrhosis. Patients/Methods This was a single‐center retrospective study. A total of 199 Japanese patients with decompensated liver cirrhosis (104 men, median age 61 years) were enrolled and received tolvaptan orally. Survival rates and new onset of AKI were monitored, and risk factors were evaluated. Results Forty‐six patients (23.1%) suffered an AKI complication and exhibited significantly poorer survival (P, In cirrhosis, AKI incidence was increased in patients with encephalopathy and poor liver function. While proton pump inhibitor/H2 blocker or kanamycin/rifaximin treatment may reduce the risk of AKI.
- Published
- 2021
9. Long‐term outcome of Wilson's disease complicated by liver disease
- Author
-
Tomomi Kogiso, Satoko Arai, Takaomi Sagawa, Katsutoshi Tokushige, Yuri Ogasawara, and Makiko Taniai
- Subjects
medicine.medical_specialty ,Cirrhosis ,medicine.medical_treatment ,RC799-869 ,Liver transplantation ,Chronic liver disease ,Gastroenterology ,Liver disease ,Internal medicine ,medicine ,Chelation therapy ,fibrosis‐4 index ,liver transplantation ,Hepatology ,business.industry ,Original Articles ,acute liver failure ,Diseases of the digestive system. Gastroenterology ,medicine.disease ,Wilson's disease ,Hepatocellular carcinoma ,Original Article ,Liver function ,business ,aspartate aminotransferase to platelet ratio index - Abstract
Background and Aim Wilson's disease (WD) is a rare inherited disease that causes systemic copper accumulation. This study examined the long‐term course of WD patients with liver disease. Methods The 12 patients (9 female patients) enrolled in the study had a median age of 28 years (range: 19–57 years) at their first visit to our hospital. Clinical course and fibrosis markers were assessed in all patients. Results The median age at diagnosis was 24 years (range: 5–42 years). One patient had acute liver failure (ALF) and 11 patients had chronic liver disease (CLD, 5 with cirrhosis). The patients were followed‐up for >20 years. The patient with ALF underwent liver transplantation; the postoperative course during the subsequent 20 years was good. Of the six patients with CLD, liver cirrhosis developed in four patients with interrupted chelating therapy. Two of the patients with cirrhosis died; one of these two patients died at 21 years after liver transplantation. However, the remaining patients with continued treatment exhibited a favorable clinical course for 30 years and none developed hepatocellular carcinoma (HCC). The duration of chelation therapy was significantly negatively correlated (P, The duration of chelation therapy for Wilson's disease complicated by liver disease was significantly negatively correlated with the fibrosis‐4 index and aspartate aminotransferase to platelet ratio index (APRI) score at the last visit.
- Published
- 2021
10. The utility of liver transplantation to treat acute liver failure caused by adult-onset Still’s disease: case reports
- Author
-
Masayoshi Harigai, Hiroto Egawa, Yuri Ogasawara, Tomomi Kogiso, Makiko Taniai, Akiko Omori, Yoshihito Kotera, Takaomi Sagawa, Katsutoshi Tokushige, Eri Sugano, Masakazu Yamamoto, and Naoko Konda
- Subjects
Adult ,medicine.medical_specialty ,Prednisolone ,medicine.medical_treatment ,Encephalopathy ,Liver transplantation ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Glucocorticoids ,Aged ,Subacute thyroiditis ,business.industry ,digestive, oral, and skin physiology ,Liver failure ,General Medicine ,Liver Failure, Acute ,Middle Aged ,Hepatology ,medicine.disease ,Colorectal surgery ,Liver Transplantation ,030220 oncology & carcinogenesis ,Female ,030211 gastroenterology & hepatology ,business ,Still's Disease, Adult-Onset ,Abdominal surgery ,medicine.drug - Abstract
Adult-onset Still’s disease (AOSD) is an inflammatory condition commonly complicated by mild liver dysfunction. However, severe liver failure is rarely reported. We report three cases of severe acute hepatic failure (ALF) associated with AOSD. We encountered three cases of acute liver failure (ALF) with encephalopathy. Case 1 was a 75-year-old female, who was started on a steroid (prednisolone, PSL) to treat AOSD; this was gradually tapered. Two months later, severe ALF developed. She died despite an increase in the PSL dose and artificial liver support. Case 2 was a 26-year-old-female taking PSL 30 mg/day to treat subacute thyroiditis. PSL was tapered, and she received methyl PSL pulse therapy and artificial liver support, but this did not cure the ALF. Liver transplantation (LT) was performed 25 days later. Three years later, the same symptoms were observed and we diagnosed AOSD. Case 3 was a 56-year-old-female who met the AOSD criteria. PSL 50 mg/day was started and then tapered. Methyl PSL pulse therapy was prescribed to treat hemophagocytic syndrome, but she required LT on hospital day 13. In AOSD cases, ALF is rarely complicated; urgent LT should be considered only for patients with AOSD-related severe ALF.
- Published
- 2021
11. Bardet-Biedl Syndrome Caused by Skipping of SCLT1 Complicated by Microvesicular Steatohepatitis
- Author
-
Kentaro Horiuchi, Makiko Taniai, Naoya Morisada, Katsutoshi Tokushige, Etsuko Hashimoto, Taito Ito, Tomomi Kogiso, Takaomi Sagawa, Motoshi Hattori, and Kenichiro Miura
- Subjects
congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,Fatty acid metabolism ,business.industry ,General Medicine ,030204 cardiovascular system & hematology ,medicine.disease ,Gastroenterology ,Obesity ,03 medical and health sciences ,chemistry.chemical_compound ,Exon ,0302 clinical medicine ,Insulin resistance ,Bardet–Biedl syndrome ,chemistry ,Internal medicine ,Retinitis pigmentosa ,Internal Medicine ,Medicine ,030211 gastroenterology & hepatology ,Steatohepatitis ,business ,Hepatic fibrosis - Abstract
We treated the case of a 22-year-old male patient with liver dysfunction. At 1 year of age, hepatic fibrosis was suspected. In addition, due to the presence of retinitis pigmentosa, renal failure, obesity, mental retardation, and hypogonadism, he was diagnosed with Bardet-Biedl syndrome (BBS). Skipping of exons 14 and 17 in the sodium channel and clathrin linker 1 (SCLT1) gene was observed. At 22 years of age, the liver enzyme levels were further elevated and a diagnosis of microvesicular steatohepatitis was made. Insulin resistance, a reduction of muscle mass, an impairment of the fatty acid metabolism, and hyperleptinemia in this syndrome may cause steatohepatitis.
- Published
- 2020
12. Characteristics of NAFLD Based on Hypopituitarism
- Author
-
Maiko Taniai, Tomomi Kogiso, Katsutoshi Tokushige, Kazuhisa Kodama, Yuichi Ikarashi, Atsuhiro Ichihara, Takaomi Sagawa, and Yasufumi Seki
- Subjects
Adult ,Leptin ,Male ,medicine.medical_specialty ,Article Subject ,Adipokine ,030209 endocrinology & metabolism ,RC799-869 ,Hypopituitarism ,Gastroenterology ,Body Mass Index ,03 medical and health sciences ,0302 clinical medicine ,Non-alcoholic Fatty Liver Disease ,Internal medicine ,Diabetes mellitus ,Nonalcoholic fatty liver disease ,medicine ,Humans ,Prolactinoma ,Retrospective Studies ,Hepatology ,business.industry ,General Medicine ,Diseases of the digestive system. Gastroenterology ,medicine.disease ,Craniopharyngioma ,Sheehan Syndrome ,Female ,030211 gastroenterology & hepatology ,Adiponectin ,business ,Hepatic fibrosis ,Research Article - Abstract
Background. Hypopituitarism and hypothalamic disorders, which induce central obesity and appetite disorder, are associated with nonalcoholic fatty liver disease (NAFLD). We retrospectively analyzed the clinical features of NAFLD patients with hypopituitarism. Patients. We examined the cases of 15 NAFLD patients with hypopituitarism (mean age, 39.4 years; males/females, 11/4). The causes of hypopituitarism were surgical in eight cases (six with craniopharyngioma and two with prolactinoma) and nonsurgical in seven cases, including unexplained hypopituitarism in five cases, Sheehan syndrome in one case, and one case that occurred after the radiation therapy. Serum adiponectin, soluble tumor necrosis factor receptor-2 (TNFR-2), and leptin levels were measured. Results. We compared the cases of the eight patients who underwent cranial surgery due to craniopharyngioma or prolactinoma and seven nonsurgical cases. The body mass index (surgery group, 30.2 ± 4.1; nonsurgery group, 29.2 ± 14.2) and the rate of diabetes (75% in surgery group, 14.3% in nonsurgery group) tended to be higher in the surgery group, and the hepatic fibrosis grade (surgery group, 3.75 ± 0.38; nonsurgery group, 1.64 ± 1.07) was significantly higher in the surgery group. The levels of adipocytokines, serum adiponectin, and serum soluble TNFR-2 showed no correlation with hepatic fibrosis, whereas the serum leptin levels were significantly correlated with liver fibrosis (R = 0.696). Conclusion. The hepatic fibrosis grade rapidly progressed in the cranial surgery cases of NAFLD patients with hypopituitarism, possibly in association with BMI, diabetes mellitus, and leptin. In such cranial surgery patients, strong interventions should be considered from the early stage, including diet education, hormone replacement, and more.
- Published
- 2020
13. A case of hemorrhage of hepatocellular carcinoma resembling a hepatic cyst arising from non-cirrhotic steatohepatitis
- Author
-
Satomi Saito, Takaomi Sagawa, Katsutoshi Tokushige, Akiko Omori, Masakazu Yamamoto, Yoshihito Kotera, Kyoko Shimizu, Masayuki Nakano, Tomomi Kogiso, Makiko Taniai, and Sho Yatsuji
- Subjects
Pathology ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Hemorrhage ,Malignancy ,Lesion ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Cyst ,Aged ,medicine.diagnostic_test ,Cysts ,business.industry ,Liver Neoplasms ,Gastroenterology ,Magnetic resonance imaging ,General Medicine ,medicine.disease ,Fatty Liver ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Reticular connective tissue ,Female ,030211 gastroenterology & hepatology ,Hepatic Cyst ,Steatohepatitis ,medicine.symptom ,business - Abstract
A 70-year-old female was found to have multiple hepatic cysts at her annual checkup. In the posterior segment of the right lobe of the liver, an 81 × 67 mm circular cystic lesion was detected by contrast-enhanced computed tomography (CT). Magnetic resonance imaging (MRI) of the cyst revealed a solid component. The cyst had a capsule-like structure and non-uniform fluid accumulation suggested bleeding. Since the lesion was enlarged and malignancy could not be ruled out, it was surgically resected. Histopathologically, reticular fibers of the liver were seen in necrotic tissue and the lesion was diagnosed as a bleeding hepatocellular carcinoma (HCC). The non-cancerous liver tissue showed non-cirrhotic steatohepatitis. This was an unusual presentation of HCC.
- Published
- 2020
14. Long‐term outcomes of non‐alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population
- Author
-
Etsuko Hashimoto, Tomomi Kogiso, Katsutoshi Tokushige, Kazuhisa Kodama, Makiko Taniai, and Takaomi Sagawa
- Subjects
Liver Cirrhosis ,Male ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Time Factors ,Comorbidity ,Disease ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Asian People ,Japan ,Non-alcoholic Fatty Liver Disease ,Predictive Value of Tests ,Diabetes mellitus ,Internal medicine ,medicine ,Humans ,Risk factor ,Retrospective Studies ,Hepatology ,Platelet Count ,business.industry ,Incidence (epidemiology) ,Liver Neoplasms ,Fatty liver ,Age Factors ,Middle Aged ,medicine.disease ,digestive system diseases ,Survival Rate ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Female ,030211 gastroenterology & hepatology ,business ,Hepatic fibrosis ,Dyslipidemia ,Follow-Up Studies - Abstract
BACKGROUND AND AIM The incidence of mortality and hepatocellular carcinoma (HCC) in patients with non-alcoholic fatty liver disease (NAFLD) has been reported, but the long-term outcomes of Japanese patients with NAFLD are not fully evaluated. METHODS We enrolled 365 Japanese patients with biopsy-confirmed NAFLD (1990-2008) followed for ≥ 6 months: 185 males (50.7%); median age (54 years); advanced fibrosis 108 (29.8%); HCC, n = 26 (7.1%); diabetes, n = 191 (52.3%); dyslipidemia, n = 234 (64.1%); and hypertension, n = 193 (52.9%). We analyzed the survival and new-onset HCC rates for hepatic fibrosis as well as complications and the treatment of lifestyle-related diseases. RESULTS During the median 7.1-year follow-up, 44 patients (12.1%) died: n = 28 liver-related (10 years liver-related death, 9.4%) and n = 16 non-liver-related deaths (10 years non-liver-related death, 4.9%). Both incidence rates were significantly higher in the advanced fibrosis group. The incidence of HCC at 10 years was 20.1% in the advanced fibrosis group, and the mortality was increased in patients with higher age, history of HCC, lower seru\m level of albumin, higher level of γ-glutamyltransferase, and insulin treatment for diabetes. Risk factors for HCC onset were higher levels of aspartate aminotransferase and triglyceride and hypertension treatment. Platelet count
- Published
- 2020
15. Prevalence of fatty liver disease after liver transplantation and risk factors for recipients and donors
- Author
-
Kentaro Horiuchi, Tomomi Kogiso, Takaomi Sagawa, Makiko Taniai, Yoshito Kotera, Hiroto Egawa, and Katsutoshi Tokushige
- Subjects
Male ,Hepatology ,fungi ,Specialties of internal medicine ,General Medicine ,Fatty liver disease (FLD) ,Middle Aged ,Liver transplantation (LT) ,Tissue Donors ,Liver Transplantation ,Everolimus (EVL) ,Treatment Outcome ,RC581-951 ,Non-alcoholic Fatty Liver Disease ,Risk Factors ,Living Donors ,Prevalence ,Humans ,Female ,Prospective Studies ,Retrospective Studies - Abstract
Introduction and objectives: Fatty liver disease (FLD) may develop in liver transplant recipients. We investigated the recipient and donor risk factors for FLD development after liver transplantation (LT). Methods: A total of 108 liver transplant recipients (54 men [50.0%]; median age, 52 [20–68] years) treated from 2011–2020 was enrolled. Three recipients died at
- Published
- 2021
16. Characteristics of acute hepatitis A virus infection before and after 2001: A hospital‐based study in Tokyo, Japan
- Author
-
Somura Yoshiko, Takaomi Sagawa, Kazuhisa Kodama, Mayuko Oda, Tomomi Kogiso, Makiko Taniai, and Katsutoshi Tokushige
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,Sexual transmission ,Sexual Behavior ,Prevalence ,medicine.disease_cause ,Gastroenterology ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,medicine ,Humans ,Tokyo ,Aged ,Retrospective Studies ,Hepatitis B virus ,Hepatology ,Coinfection ,business.industry ,Incidence (epidemiology) ,Age Factors ,Hepatitis A ,Sexually Transmitted Diseases, Viral ,Middle Aged ,Hepatitis B ,medicine.disease ,Hospitals ,030220 oncology & carcinogenesis ,Acute Disease ,Female ,030211 gastroenterology & hepatology ,Syphilis ,business ,Biomarkers - Abstract
BACKGROUND AND AIM The incidence of acute hepatitis A [AH (A)] is decreasing because of improvements in hygiene; however, cases of sporadic severe hepatitis are still being reported. We assessed the epidemiology of AH (A) in Japan. METHODS This was a hospital-based retrospective study, in which 126 AH (A) patients (96 men [76%], median age 39 [range, 19-66] years) were enrolled. Patients diagnosed with AH (A) before 2001 (n = 79) and after 2001 (n = 47) were compared. RESULTS The incidence of AH (A) showed peaks in 1990, 1999, and 2018. After 2001, one patient had hepatitis B virus, four had human immunodeficiency virus, and three had syphilis coinfections. Before and after 2001, HAV was transmitted, respectively, by raw oysters (28% and 26%), overseas travel (19% and 28%), and sexual contact (0% and 19%) (P
- Published
- 2019
17. Hepatocellular carcinoma after direct-acting antiviral drug treatment in patients with hepatitis C virus
- Author
-
Katsutoshi Tokushige, Hiroto Egawa, Makiko Taniai, Kazuhisa Kodama, Masakazu Yamamoto, Satoshi Katagiri, Tomomi Kogiso, and Takaomi Sagawa
- Subjects
Ledipasvir ,medicine.medical_specialty ,Elbasvir ,Daclatasvir ,Hepatology ,Sofosbuvir ,business.industry ,Gastroenterology ,digestive system diseases ,Ombitasvir ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,chemistry ,Grazoprevir ,Paritaprevir ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Asunaprevir ,030211 gastroenterology & hepatology ,business ,medicine.drug - Abstract
Background and Aim Given the use of direct-acting antivirals (DAAs) to treat hepatitis C virus (HCV), their effects on hepatocarcinogenesis should be determined. Methods This study enrolled 349 patients with HCV who underwent DAA treatment at our hospital between 2014 and 2018. Their median age was 65 years, and 184 were male; 301 cases were of HCV serotype 1, and 48 were of serotype 2. The DAA treatment was daclatasvir/asunaprevir in 107 cases, sofosbuvir (SOF)/ledipasvir in 147 cases, ritonavir-boosted ombitasvir/paritaprevir in 28 cases, elbasvir/grazoprevir in 19 cases, and SOF/ribavirin in 48 cases. The patients' histories included hepatocellular carcinoma (HCC) in 45 cases, liver transplant (LT) in 10 cases, and kidney transplant (KT) in 17 cases. Results Sustained virological responses occurred in 335 cases (96%). DAA treatment was initiated a median of 16.3 months after HCC treatment. After DAA treatment, 15 cases (33%) had recurrence of HCC after a median of 11.6 months, and 3 cases (1%) developed de novo HCC. Six LT patients and one KT patient had HCC; however, no HCC was observed after DAA. The incidence of HCC was significantly higher in patients with multiple HCC treatments in the Cox hazard model (hazard ratio 1.664, 95% confidence interval 1.134-2.441, P < 0.01). Surgical resection or LT reduced the risk of HCC. Conclusions DAA did not increase the rate of HCC, even in immunosuppressed patients. However, careful follow-up for HCC recurrence is required in previously treated cases.
- Published
- 2018
18. Hepatocellular carcinoma after direct‐acting antiviral drug treatment in patients with hepatitis C virus
- Author
-
Tomomi, Kogiso, Takaomi, Sagawa, Kazuhisa, Kodama, Makiko, Taniai, Satoshi, Katagiri, Hiroto, Egawa, Masakazu, Yamamoto, and Katsutoshi, Tokushige
- Subjects
direct‐acting antivirals ,hepatocarcinogenesis ,Original Article ,Original Articles ,hepatocellular carcinoma ,digestive system diseases - Abstract
Background and Aim Given the use of direct‐acting antivirals (DAAs) to treat hepatitis C virus (HCV), their effects on hepatocarcinogenesis should be determined. Methods This study enrolled 349 patients with HCV who underwent DAA treatment at our hospital between 2014 and 2018. Their median age was 65 years, and 184 were male; 301 cases were of HCV serotype 1, and 48 were of serotype 2. The DAA treatment was daclatasvir/asunaprevir in 107 cases, sofosbuvir (SOF)/ledipasvir in 147 cases, ritonavir‐boosted ombitasvir/paritaprevir in 28 cases, elbasvir/grazoprevir in 19 cases, and SOF/ribavirin in 48 cases. The patients’ histories included hepatocellular carcinoma (HCC) in 45 cases, liver transplant (LT) in 10 cases, and kidney transplant (KT) in 17 cases. Results Sustained virological responses occurred in 335 cases (96%). DAA treatment was initiated a median of 16.3 months after HCC treatment. After DAA treatment, 15 cases (33%) had recurrence of HCC after a median of 11.6 months, and 3 cases (1%) developed de novo HCC. Six LT patients and one KT patient had HCC; however, no HCC was observed after DAA. The incidence of HCC was significantly higher in patients with multiple HCC treatments in the Cox hazard model (hazard ratio 1.664, 95% confidence interval 1.134–2.441, P < 0.01). Surgical resection or LT reduced the risk of HCC. Conclusions DAA did not increase the rate of HCC, even in immunosuppressed patients. However, careful follow‐up for HCC recurrence is required in previously treated cases.
- Published
- 2018
19. Giant Hepatic Hemangioma Causing Prolonged Fever and Indicated for Resection.
- Author
-
Chihiro Yoshimizu, Shunichi Ariizumi, Tomomi Kogiso, Takaomi Sagawa, Makiko Taniai, Goro Honda, Hiroto Egawa, and Katsutoshi Tokushige
- Published
- 2022
- Full Text
- View/download PDF
20. Outcomes of Japanese patients with non-alcoholic fatty liver disease according to genetic background and lifestyle-related diseases
- Author
-
Tomomi Kogiso, Takaomi Sagawa, Etsuko Hashimoto, Makiko Taniai, Katsutoshi Tokushige, and Kazuhisa Kodama
- Subjects
Adult ,Male ,medicine.medical_specialty ,Patatin-like phospholipase 3 (PNPLA3) ,Adolescent ,Genotype ,Biopsy ,Specialties of internal medicine ,Single-nucleotide polymorphism ,Subgroup analysis ,Disease ,Gastroenterology ,Polymorphism, Single Nucleotide ,Non-alcoholic fatty liver disease (NAFLD) ,Young Adult ,Japan ,Single nucleotide polymorphism (SNP) ,Non-alcoholic Fatty Liver Disease ,Internal medicine ,medicine ,Humans ,Mortality ,Life Style ,ALDH2 ,Aged ,Aldehyde dehydrogenase 2 (ALDH2) ,Aged, 80 and over ,Hepatology ,medicine.diagnostic_test ,business.industry ,Aldehyde Dehydrogenase, Mitochondrial ,Hazard ratio ,Fatty liver ,General Medicine ,DNA ,Middle Aged ,medicine.disease ,RC581-951 ,Hepatocellular carcinoma ,Female ,Liver function tests ,business ,Genetic Background - Abstract
Introduction and objectives Genetic background may be involved in the mechanisms of liver injury and the development of non-alcoholic fatty liver disease (NAFLD). However, its contributions to the long-term outcome of NAFLD have been unclear. Methods We enrolled 314 Japanese patients with biopsy-confirmed NAFLD from 2000 to 2018 (161 men [51.3%]; median age, 53 [14–84] years; 114 with advanced fibrosis [37.5%]) in the patients without hepatocellular carcinoma at diagnosis. Genomic DNA was extracted from peripheral blood and single nucleotide polymorphisms (SNPs) were analyzed. Associations of mortality with patatin-like phospholipase 3 (PNPLA3) and aldehyde dehydrogenase 2 (ALDH2) were analyzed. Finally, a subgroup analysis according to lifestyle-related disease was performed. Results During the median 7 years of follow-up, 20 patients (6.4%) died (13 liver-related [4.1%] and 7 non-liver-related deaths [2.2%]). Patients with ALDH2 (non-GG genotype) who had reduced alcohol metabolism tended to have a poor prognosis (p = 0.06). Patients carrying both risk SNPs of PNPLA3 (GG) and ALDH2 (non-GG) had a significantly poor prognosis (p = 0.01). In the subgroup analysis, patients with PNPLA3 (GG) who were non-diabetics (p = 0.06) or non-dyslipidemic (p = 0.03), with ALDH2 (non-GG) who were non-dyslipidemic (p = 0.01) or hypertensive (p = 0.03), also had a poor prognosis. The Cox analysis revealed that ALDH2 (non-GG) was associated with a poor prognosis (Hazard ratio: 4.568, 95% Confidence Interval: 1.294–16.131, p = 0.02) similar to the liver function tests. Conclusions Genetic background may affect NAFLD prognosis and ALDH2 SNP could predict the outcome.
- Published
- 2020
21. Development and course of diabetes according to genetic factors and diabetes treatment among patients with nonalcoholic fatty liver disease
- Author
-
Katsutoshi Tokushige, Kazuhisa Kodama, Tomomi Kogiso, Makiko Taniai, Etsuko Hashimoto, and Takaomi Sagawa
- Subjects
0301 basic medicine ,Male ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Incretin ,030209 endocrinology & metabolism ,Single-nucleotide polymorphism ,Gastroenterology ,Polymorphism, Single Nucleotide ,03 medical and health sciences ,0302 clinical medicine ,Non-alcoholic Fatty Liver Disease ,Internal medicine ,Diabetes mellitus ,Nonalcoholic fatty liver disease ,Genotype ,Medicine ,Humans ,Genetic Predisposition to Disease ,Sodium-Glucose Cotransporter 2 Inhibitor ,Sodium-Glucose Transporter 2 Inhibitors ,030109 nutrition & dietetics ,Nutrition and Dietetics ,business.industry ,Incidence (epidemiology) ,Insulin ,Membrane Proteins ,Lipase ,medicine.disease ,Diabetes Mellitus, Type 2 ,business - Abstract
Many patients with nonalcoholic fatty liver disease (NAFLD) also have diabetes. However, the genetic factors associated with diabetes in NAFLD are unclear. In this study, we investigated the clinical course and risk factors of diabetes development.A total of 544 patients (275 men; 50.6%) with a median age of 53 y and biopsy-confirmed NAFLD enrolled in the study. Patatin-like phospholipase 3 and voltage-gated potassium channel KQT-like subfamily member 1 (KCNQ1) single nucleotide polymorphisms were identified in 287 cases. There were 272 patients without diabetes, and 64, 141, and 67 patients with diabetes not treated with an oral hypoglycemic agent, treated with an oral hypoglycemic agent, and treated with insulin, respectively. Changes in biochemical parameters and body weight over a 1-y period were determined in patients treated with incretin agents (n = 91), a sodium glucose cotransporter 2 inhibitor (n = 19), or both (n = 33). The prevalence and risk factors for diabetes development among patients with NAFLD were determined in nondiabetic patients.Among patients with NAFLD, half of the patients had diabetes and the incidence was high in those with advanced fibrosis. Reduction in body weight was higher after sodium glucose cotransporter 2 inhibitor treatment (P = .050) and in KCNQ1 CC genotype patients (P.05). Reduction in hemoglobin A1c level was significantly lower in patatin-like phospholipase 3 GG subjects (P.05). De novo diabetes developed in 44 patients (10-y incidence: 17.9%), especially in obese (P = .046) and KCNQ1 CC genotype patients (P.01).Patient genetic background affected treatment response and incidence of diabetes in patients with NAFLD.
- Published
- 2020
22. Characteristics of hepatocellular carcinoma arising from Fontan-associated liver disease
- Author
-
Masakazu Yamamoto, Tomomi Kogiso, Takaomi Sagawa, Katsutoshi Tokushige, Etsuko Hashimoto, and Hisashi Sugiyama
- Subjects
medicine.medical_specialty ,Cirrhosis ,Hepatology ,business.industry ,Incidence (epidemiology) ,medicine.medical_treatment ,medicine.disease ,Gastroenterology ,digestive system diseases ,Fontan procedure ,03 medical and health sciences ,Liver disease ,0302 clinical medicine ,Infectious Diseases ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Internal medicine ,Medicine ,030211 gastroenterology & hepatology ,Polysplenia ,business ,Transcatheter arterial chemoembolization ,neoplasms ,Survival rate - Abstract
AIM Hepatocellular carcinoma (HCC) can arise from Fontan-associated liver disease (FALD); this is known as FALD-HCC. The clinical features of FALD-HCC are unclear. Thus, we examined the incidence and clinical characteristics of FALD-HCC. METHODS From 1972 to 2019, 122 patients developed liver disease after undergoing Fontan procedures. HCC was diagnosed in 12 (9.8%) FALD patients. We compared FALD-HCC and non-HCC patients. RESULTS The incidence of HCC was 0.8% and 2.9% in FALD 10 and 20 years after the Fontan procedure, respectively. The median age of patients at diagnosis of HCC was 32.5 years (range 20.6-46.1 years), and seven of the 12 patients were men. Patients with FALD-HCC had a higher incidence of liver cirrhosis and polysplenia than non-HCC patients. Liver tumors were detected as single nodules in eight patients, and the median diameter was 47 mm (range 11-105 mm). HCC was treated by surgical resection in two patients, transcatheter arterial chemoembolization or chemotherapy in three patients, and proton beam therapy in four patients. Three patients could not be treated because of their poor condition. Four patients died of liver/cardiac failure and HCC, and HCC was controlled in three patients. The survival rate after 25 years was significantly lower in patients with FALD-HCC than non-HCC patients (68.6% vs. 97.9%, respectively; P
- Published
- 2020
23. A case of Fontan-related hepatocellular carcinoma successfully treated with proton beam therapy
- Author
-
Yuri Ogasawara, Katsutoshi Tokushige, Kazuhisa Kodama, Hideyuki Sakurai, Tomomi Kogiso, Haruko Numajiri, Makiko Taniai, and Takaomi Sagawa
- Subjects
Adult ,medicine.medical_specialty ,Liver tumor ,Carcinoma, Hepatocellular ,Radiofrequency ablation ,medicine.medical_treatment ,Transposition of Great Vessels ,Heterotaxy Syndrome ,Fontan Procedure ,Inferior vena cava ,law.invention ,Fontan procedure ,03 medical and health sciences ,0302 clinical medicine ,Postoperative Complications ,law ,medicine ,Proton Therapy ,Humans ,medicine.diagnostic_test ,business.industry ,Liver Diseases ,Liver Neoplasms ,Gastroenterology ,Magnetic resonance imaging ,General Medicine ,medicine.disease ,Magnetic Resonance Imaging ,medicine.vein ,Great arteries ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,030211 gastroenterology & hepatology ,Polysplenia ,Female ,Radiology ,business ,Tomography, X-Ray Computed - Abstract
A 27-year-old woman was admitted to our hospital due to a liver tumor. She had been born late at 41 weeks of gestation and had heterotaxy syndrome, polysplenia, and complete transposition of the great arteries. She underwent percutaneous balloon angioplasty at 5 years of age and the Fontan procedure at 6 years of age. At 25 years of age, computed tomography detected liver congestion. Her alpha-fetoprotein level increased from 13 to 2098 ng/dL (L3 fraction 1.8%) at 27 years of age. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging showed a 22-mm liver tumor in the second liver segment. The liver tumor was enhanced in the arterial phase and washed-out in the hepatobiliary phase; the patient was, therefore, diagnosed with hepatocellular carcinoma. Radiofrequency ablation and surgery were not indicated due to the proximity of the tumor to the inferior vena cava. Therefore, proton beam therapy was selected as conservative therapy, and a dose of 74 Gray equivalents in 37 fractions was administered at the University of Tsukuba Hospital. There were no severe adverse events and she survived for 38 months after treatment without recurrence.
- Published
- 2019
24. Impact of continued administration of tolvaptan on cirrhotic patients with ascites
- Author
-
Makiko Taniai, Kazuhisa Kodama, Tomomi Kogiso, Takaomi Sagawa, and Katsutoshi Tokushige
- Subjects
Adult ,Liver Cirrhosis ,Male ,medicine.medical_specialty ,Tolvaptan ,Renal function ,Gastroenterology ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,lcsh:RA1190-1270 ,Ammonia ,Internal medicine ,Ascites ,medicine ,Body weight reduction ,Humans ,Pharmacology (medical) ,Vasopressin V2-receptor antagonist ,Serum Albumin ,lcsh:Toxicology. Poisons ,Aged ,Pharmacology ,Prothrombin time ,Aged, 80 and over ,medicine.diagnostic_test ,business.industry ,lcsh:RM1-950 ,Body Weight ,Albumin ,Retrospective cohort study ,Middle Aged ,Long-term outcome ,lcsh:Therapeutics. Pharmacology ,Treatment Outcome ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Female ,Liver function ,medicine.symptom ,business ,Complication ,Antidiuretic Hormone Receptor Antagonists ,medicine.drug ,Research Article - Abstract
Background The vasopressin V2-receptor antagonist tolvaptan is used to treat cirrhotic patients with ascites. We investigated the outcome of long-term treatment. Methods This was a single-center retrospective study. Overall, 170 cirrhotic patients (95 males, median age 63 years) were enrolled and received tolvaptan orally after hospitalization for ascites, which included treatment with conventional diuretics. We compared patients who withdrew tolvaptan treatment after
- Published
- 2018
25. Elevated α-Fetoprotein in the Absence of Carcinoma Caused by Relapse of Hepatitis C Viral Infection after Liver Transplantation
- Author
-
Masakazu Yamamoto, Yoshihito Kotera, Katsutoshi Tokushige, Hiroto Egawa, Takaomi Sagawa, and Tomomi Kogiso
- Subjects
medicine.medical_specialty ,Hepatitis c viral ,Cirrhosis ,business.industry ,Hepatitis C virus ,medicine.medical_treatment ,virus diseases ,Case Report ,General Medicine ,Liver transplantation ,medicine.disease ,medicine.disease_cause ,Gastroenterology ,digestive system diseases ,Liver ,Internal medicine ,Hepatocellular carcinoma ,Rare case ,medicine ,Carcinoma ,business - Abstract
We report a rare case of marked elevation of α-fetoprotein in the absence of hepatocellular carcinoma caused by a relapse of hepatitis C virus (HCV) infection. A 58-year-old man underwent liver transplantation to treat hepatocellular carcinoma caused by HCV-related liver cirrhosis. The HCV was of genotype 2a, and the ribonucleic acid titer was >8.0 log IU/mL. Direct-acting antiviral drugs were prescribed for 12 weeks; however, the HCV infection relapsed after treatment had ended, and α-fetoprotein levels increased to 8,981 ng/mL. Imaging did not reveal any malignancies. The patient initiated interferon therapy, at which time AFP levels decreased, and the HCV was successfully cleared.
- Published
- 2018
26. Elevated α-Fetoprotein in the Absence of Carcinoma Caused by Relapse of Hepatitis C Viral Infection after Liver Transplantation.
- Author
-
Tomomi Kogiso, Takaomi Sagawa, Yoshihito Kotera, Hiroto Egawa, Masakazu Yamamoto, and Katsutoshi Tokushige
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.